Recent developments include licensing agreements, collaborations, financial results announcements, and corporate governance actions.

• Evogene announced a special general meeting to approve share options for the CEO in March 2026 [N1].
• The company licensed the microbiome-based cancer therapeutic BMC128 to Shanghai Lishan Biopharmaceuticals under an exclusive worldwide agreement in February 2026 [N2][S16].
• Evogene reported its third quarter 2025 earnings and provided a financial snapshot in January 2026 [N3].
• Evogene and Unravel Biosciences announced a collaboration to develop a therapy to reverse neurological damage in demyelinating disorders in January 2026 [N4].
• The company reported quarterly earnings results in May 2025 [N7].
• Evogene sold the majority of Lavie Bio to ICL under undisclosed terms in April 2025 [N8].
• Evogene reported its fourth quarter and full year 2025 financial results in March 2026 [S2].

Evogene's advanced computational platform and its integration with biological validation provide a strong foundation for developing innovative products in agriculture and human health. The company's strategic licensing agreements, such as the exclusive worldwide license of BMC128 to Shanghai Lishan Biopharmaceuticals, demonstrate its ability to monetize its technologies. Participation in government-sponsored consortia and collaborations with other biotech firms expand its research capabilities and potential product pipeline. Strong liquidity and ongoing R&D investment support continued innovation. The company's diversified approach across multiple biotech segments may provide multiple avenues for value creation.

Evogene operates in highly competitive and regulated biotechnology sectors, where product development and commercialization face significant scientific and regulatory hurdles. The company reported a net loss for fiscal year 2025, indicating ongoing challenges in achieving profitability. Licensing agreements and collaborations may be subject to milestone and royalty contingencies, which can impact revenue visibility. Restrictions and obligations under Israeli Innovation Law related to government grants may limit flexibility in technology transfer and manufacturing. The termination of the licensing agreement with Corteva and the sale of majority of Lavie Bio may reflect challenges in commercializing certain assets. Market and technological risks inherent in biotech innovation remain significant.

Evogene's moat is anchored in its proprietary CPB platform that integrates big-data analytics, interconnected data hubs, and proprietary algorithms, enabling advanced computational predictions validated through biological testing. The company's participation in government-sponsored consortia and receipt of grants provide access to cutting-edge research and funding. Its portfolio of licensing agreements, including exclusive rights to microbiome-based therapeutics and bio-fungicides, along with collaborations in genome editing and neurological therapies, contribute to its competitive positioning. Regulatory and grant-related restrictions under Israeli Innovation Law create barriers to technology transfer, potentially protecting intellectual property. However, the company's moat is subject to the challenges of biotechnology innovation, regulatory approvals, and competitive pressures in the agriculture and human health sectors.

• Regulatory and Grant Restrictions: Evogene has received Israeli government grants subject to the Innovation Law, which imposes restrictions on manufacturing location, technology transfer, and royalty payments. Failure to comply may result in penalties, repayment obligations, and criminal proceedings [S1][S6][S13].
• Financial Performance and Profitability: The company reported a net loss of $7.83 million for fiscal year 2025 despite generating revenue of $3.85 million, indicating ongoing challenges in achieving profitability and sustainable cash flow [S7].
• Dependence on Licensing and Collaborations: Evogene's business model relies on licensing agreements and collaborations, which may be subject to termination, milestone achievement, and royalty contingencies, affecting revenue stability. For example, the termination of the Corteva licensing agreement and sale of Lavie Bio majority stake [S1][N8].
• Market and Technological Risks: Biotechnology development involves scientific uncertainty, regulatory approvals, and competitive pressures that may impact product development timelines and commercial success.

• Evogene Ltd. is an Israeli company engaged in biotechnology with a focus on agriculture and human health segments [S1].
• The company operates subsidiaries including Biomica Ltd. and Lavie Bio Ltd. [S1].
• Evogene's business includes licensing microbiome-based therapeutics, such as the exclusive worldwide licensing agreement for BMC128 to Shanghai Lishan Biopharmaceuticals, which grants Lishan Biotech rights to develop, manufacture, and commercialize BMC128, with Biomica eligible for milestone payments and royalties [S1][N2][S16].
• Evogene has a licensing agreement with Corteva Agriscience for bio-fungicides developed by Lavie Bio, which was terminated in November 2024, with Lavie Bio regaining rights and receiving a $5 million initial payment [S1][S5].
• Evogene sold the majority of Lavie Bio to ICL under undisclosed terms [N8].
• The company has a framework agreement with ENI to sell proprietary castor seeds for biofuel production in Africa, with deliveries in Q1 2025 totaling approximately $2.168 million, but no further orders as of the latest report [S1].
• Evogene collaborates in consortia sponsored by the Israeli Innovation Authority (IIA), including the Phenomics Consortium for precision agriculture and the CRISPR-IL Consortium for AI-based genome editing across multiple species [S1][S4].
• Evogene invests in maintaining its CPB platform, which includes big-data databases, interconnected data hubs, proprietary analysis, and prediction algorithms, supported by laboratories and greenhouses for biological validation [S14].
• As of December 31, 2025, 31 employees (about 59.6% of workforce) were engaged full-time in research and development [S14].
• Evogene has received various grants from Israeli government agencies and the EU, including IIA grants with associated royalty and manufacturing restrictions under the Innovation Law [S1][S6][S13].
• The company reported full-year 2025 financial results with revenue of $3.853 million and a net loss of $7.827 million as of December 31, 2025 [S7][S8].
• Basic and diluted EPS were both reported as $1.08 per share for the fiscal year ended December 31, 2025 [S7].
• Liquidity as of December 31, 2025 included cash and equivalents of $12.956 million, current assets of $15.631 million, current liabilities of $3.444 million, with a current ratio of 4.54 and cash ratio of 3.76 [S7][S12].
• Evogene announced a special general meeting to approve share options for the CEO in March 2026 [N1].
• Evogene and Unravel Biosciences announced a collaboration to develop a first-in-class therapy to reverse neurological damage in demyelinating disorders [N4].
• Evogene's recent quarterly earnings and financial results have been publicly reported and discussed in investor calls [N3][N7][S2].